{'52WeekChange': -0.24324328,
 'SandP52WeekChange': 0.0644362,
 'address1': '1180 Seminole Trail',
 'address2': 'Suite 495',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.42,
 'askSize': 1200,
 'averageDailyVolume10Day': 305512,
 'averageVolume': 493065,
 'averageVolume10days': 305512,
 'beta': None,
 'beta3Year': None,
 'bid': 1.4,
 'bidSize': 1400,
 'bookValue': 0.522,
 'category': None,
 'circulatingSupply': None,
 'city': 'Charlottesville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.43,
 'dayLow': 1.38,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.197,
 'enterpriseToRevenue': None,
 'enterpriseValue': 9929813,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.4634286,
 'fiftyTwoWeekHigh': 3.17,
 'fiftyTwoWeekLow': 1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 8389308,
 'forwardEps': -0.67,
 'forwardPE': -2.0895522,
 'fromCurrency': None,
 'fullTimeEmployees': 3,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.31743,
 'heldPercentInstitutions': 0.0589,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/adialpharma.com',
 'longBusinessSummary': 'Adial Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'of therapeutic agents for the treatment of alcohol '
                        'use disorders. Its lead product is AD04, a selective '
                        'serotonin-3 antagonist that has completed Phase IIb '
                        'clinical trials for the treatment of nausea and '
                        'emesis. The company was founded in 2010 and is based '
                        'in Charlottesville, Virginia.',
 'longName': 'Adial Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 18829440,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_112638788',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -8185591,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '434-422-9800',
 'previousClose': 1.425,
 'priceHint': 4,
 'priceToBook': 2.6819923,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.43,
 'regularMarketDayLow': 1.38,
 'regularMarketOpen': 1.41,
 'regularMarketPreviousClose': 1.425,
 'regularMarketPrice': 1.41,
 'regularMarketVolume': 119684,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13449600,
 'sharesPercentSharesOut': 0.0043,
 'sharesShort': 57747,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8239,
 'shortName': 'Adial Pharmaceuticals, Inc',
 'shortPercentOfFloat': 0.0055,
 'shortRatio': 0.05,
 'startDate': None,
 'state': 'VA',
 'strikePrice': None,
 'symbol': 'ADIL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.786,
 'twoHundredDayAverage': 1.5373381,
 'volume': 119684,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.adialpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '22901'}